AB-205 / Angiocrine 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    News 
  • ||||||||||  AB-205 / Angiocrine
    AB-205 (E-CEL®) Cell Therapy in Older Subjects with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (ASH 2021) -  Nov 5, 2021 - Abstract #659; Author: Michael Scordo, MD1; Lihua E Budde, MD, PhD2,3; Mehrdad Abedi, MD4,5; Carolyn Mulroney, MD6; Bita Fakhri, MD, MPH7; Attaphol Pawarode, MD PhD8; Bhagirathbhai Dholaria, MBBS9,10; Geoffrey Shouse, DO, PhD11; Edward Kavalerchik, MD12; Sanjay K. Aggarwal, MB BChir, MRCP12; Muzaffar H. Qazilbash, MD13; Paul Finnegan, MD14; Sergio A Giralt, MD15; Presentation Time: December 13, 2021; 11:30-11:45   
    In addition, neutrophil and particularly platelet recoveries were timely. Single injection of 20M cells/kg has been determined to be the dose for the planned registration Phase 3 trial.